Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).

Affiliation auteurs!!!! Error affiliation !!!!
TitreFinal analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).
Type de publicationJournal Article
Year of Publication2015
AuteursSmith MRaymond, De Bono JSebastian, Sternberg CN, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman AM, Hoelzer W, De Wit R, Boegemann M, Saad F, Cruciani G, Thiery-Vuillemin A, Feyerabend S, Miller K, Ramies DAlbert, Hessel C, Weitzman A, Fizazi K
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume33
Date PublishedMAR 1
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/jco.2015.33.7_suppl.139